Inferra AIResearch Tools

Inferra AI / Company / KALV

KalVista Pharmaceuticals, Inc.

KALV · Health Care

Last earnings Mar 25, 2026

Key results

Revenuequarter

$13.7 million

Third Quarter Financial Results Recognized $13.7 million in net product revenue for the three months ended September 30, 2025.

SEC original ↗KalVista Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Nov 10, 2025

Cost of revenue was $1.2 million for the three months ended September 30, 2025 which included EKTERLY manufacturing and inventory overhead costs incurred after US approval.

SEC original ↗KalVista Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Nov 10, 2025

AI analysis

Q3 2025 · reported Nov 10, 2025

Based on: Earnings release + parent 8-K — transcript not held

Revenue · Q3 2025
$13.7M
EX-99 · Nov 10, 2025

Headline figures

MetricQ3 2025Prior qtrYear ago
Revenue$13.7 million——

EX-99 · Nov 10, 2025

Guidance · company-stated

No guidance located in the held release

Next earningsNo verified date on fileNo date is estimated or imported
General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

(Nasdaq: KALV), today provided an operational update and reported financial results for the third quarter ended September 30, 2025

Based on: Earnings release + parent 8-K — transcript not held

Guidance & outlook

No guidance located in the held release

Strategy & priorities

With the successful closing of our recent $144 million convertible note offering, we have the financial resources to continue advancing our global launch strategy and building long-term growth.

SEC original ↗KalVista Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Nov 10, 2025

Forward-looking statements can be identified by words such as: anticipate, intend, plan, goal, seek, believe, project, estimate, expect, position, strategy, future, likely, may, should, will and similar references to future periods.

SEC original ↗KalVista Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Nov 10, 2025

Risks & headwinds

These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect.

SEC original ↗KalVista Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Nov 10, 2025

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care
Documents

Filings

31 documents

Earnings releases

11 documents

Presentations

0 documents

No presentations for KalVista Pharmaceuticals, Inc. are held in this edition of the library.

Transcripts

0 documents

No transcripts for KalVista Pharmaceuticals, Inc. are held in this edition of the library.

See also the earnings calendar for every tracked company’s next earnings date.